OQL061 / OnQuality Pharma - LARVOL DELTA

OQL06x, a gut-restricted janus kinase inhibitor to control epidermal growth factor receptor inhibitor-induced diarrhea (AACR 2023) - "Selected compounds were tested in vivo with afatinib (40mg/kg) plus OQL06x, tofacitinib, or placebo started on Day 1 and continued for 10 days in a rat EGFRi-induced diarrhea model. Our research demonstrated that an orally administered, gut-restricted JAK inhibitor, OQL06x, can reduce EGFR inhibitor-induced diarrhea severity. Additionally, OQL06x’s gut restriction and low systemic exposure may reduce the risk of serious AEs observed with other oral JAK inhibitors and limit the potential for interference with EGFR inhibition anti-cancer efficacy."

Oncology • EGFR • IL6 • JAK1 • STAT3

OnQuality Pharmaceuticals Presented Preclinical Data for OQL025 and OQL06x, Novel Therapeutics for EGFR inhibitor-induced acneiform rash and diarrhea, at the AACR Annual meeting (PRNewswire) - "OnQuality Pharmaceuticals...announced it presented preclinical data on OQL025 and OQL06x, at the American Association for Cancer Research (AACR) annual meeting. The conference is being held in Orlando, FL, April 14-19, 2023....In murine models of diarrhea caused by afatanib, orally administered OQL06x reduced the severity of EGFR inhibitor-induced diarrhea when compared to placebo. The improvement was accomplished with minimal systemic exposure, as OQL06x has been designed to have gut-restrictive properties, reducing the potential to cause systemic toxicities and interference with EGFR inhibitor anti-cancer efficacy."

Preclinical • Oncology